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Chemoresistance is a major problem during cancer treat-
ment. ATP-binding cassette (ABC) transporter efflux is
mainly responsible for this chemotherapeutics resistance
of the tumour cells. We have recently observed that in the
presence of statins SH-SY5Y neuroblastoma cells show
enhanced susceptibility to doxorubicin-induced apopto-
sis which cannot be explained by simple additivity. In
order to monitor ABC transporter activity as a possible
source of statin-mediated additivity in doxorubicin-
induced apoptosis, calcein uptake and release were ana-
lysed in human SH-SY5Y neuroblastoma cells. Simvasta-
tin inhibited calcein uptake and release to the same extent
as the well-described 1st generation ABC transporter
inhibitor verapamil. Using the fluorescence behaviour of
doxorubicin the accumulation of the anthracycline in SH-
SY5Y neuroblastoma cells was visualised by confocal
microscopy. The cumulating fluorescence intensity
showed significant acceleration and accumulation under
atorvastatin treatment. P-glycoprotein (ABCB1) is a
heavyly glycosylated transporter for cytotoxic com-
pounds. The protein appears as a double band, represent-
ing a mature fully glycosylated protein (~180 kDa) and a
partially deglycosylated immature protein (~140 kDa)
[1]. Atorvastatin reduced the mature 180 kDa protein
band, suggesting an impairment of glycosylation. Treat-
ment of the cells with tunicamycin, an inhibitor of the
endogenous protein glycosylation in the endopolasmic
reticulum, leads to the detection of the complete deglyco-
sylated immature protein (~110 kDa). This assumption is
corroborated by additional N-glycosidase F (PNGase)
treatment of the human SH-SY5Y cells. The functional rel-
evance of the deglycosylation of P-glycoprotein has been
confirmed by enhanced doxorubicin accumulation in
PNGase F-treated SH-SY5Y cells. In order to circumvent
limited biological significance of the degenerated SH-
SY5Y cell line primary human neuroblastoma cells were
investigated. Similary, in the presence of statins enhanced
doxorubicin accumulation was detectable and thereby
corroborated the above described principle of action.
Taken together, simvastatin and atorvastatin reduce the
glycosylation of P-glycoprotein. Hence, statins reduce the
activity of P-glycoprotein, which leads to an enhanced
intracellular accumulation of doxorubicin. This explains
the potentiated apoptosis by co-application of simvasta-
tin and doxorubicin.
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